Phase 2 Brain Cancer Trial, Recruiting NCT07193654 Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University Condition: Brain Cancer
Back to Brain Cancer

Phase 2 Brain Cancer Trial, Recruiting

NCT07193654
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged 18 to 75 of any gender
  • People who have been recently diagnosed with a high-grade (grade 4) brain tumour, with at least one measurable tumour area, and where scans suggest the tumour has spread toward the fluid-filled spaces or outer coverings of the brain
  • People who had surgery that involved opening into the fluid-filled spaces inside or around the brain
  • People in whom cancer cells were found in the fluid surrounding the brain and spinal cord, before radiation treatment began
  • People who are generally well enough to care for themselves, with a performance score in a certain range (confirm with trial site), and who are expected to live at least 3 months
  • People whose neurological symptoms (such as weakness or coordination problems) have been stable for more than 7 days
  • People whose blood counts meet minimum levels — including white blood cells, red blood cells, and platelets — as assessed by a doctor
  • People whose blood clotting results fall within an acceptable range, as assessed by a doctor
  • People whose liver and kidney function results fall within acceptable ranges, as assessed by a doctor
  • People who agree to use effective contraception from the start of the trial until at least 3 months after the last dose

Who may not be able to join:

  • People who are pregnant or breastfeeding
  • People who have had an active infection in the 7 days before starting the study treatment that required antibiotics given through a drip, or who are taking a blood-thinning medication called warfarin for treatment purposes
  • People who have had another cancer in the past 5 years
  • People with a history of HIV or AIDS, a history of immune system problems, or an active condition where the immune system attacks the body and requires ongoing treatment
  • People with serious medical, neurological, or mental health conditions that would make it difficult to follow the full study treatment and attend all required assessments
  • People whose brain drainage tube has broken, or who are unable to have a lumbar puncture (a procedure to collect fluid from around the spinal cord)
  • People with uncontrolled long-term conditions such as diabetes, heart failure, liver cirrhosis, or chronic kidney disease

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: +86-571-87783521

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Registry
ClinicalTrials.gov
Start date
1 April 2025
Est. completion
1 April 2027

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Safety assessment

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov